chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Immediately following administration (approx 3:15pm) patient mentioned having a "funny taste in her mouth".  She described it as a metallic taste. This persisted for about 7 or 8  minutes. At that time, she stated that the taste went away and she had a headache just over her left eye. At about 15 minutes post-vaccination, the patient said the headache was "mostly better" and that she was ready to leave. I did advise her to take Tylenol to treat the headache if needed.
Dizzy; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (Dizzy) in an 81-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 27-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 28-Jan-2021, the patient experienced DIZZINESS (Dizzy). At the time of the report, DIZZINESS (Dizzy) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medication information not reported. Treatment information not provide by the reporter.   Most recent FOLLOW-UP information incorporated above includes: On 16-Apr-2021: Patient denied consent for further follow up.
Immediately got redness of injection site feeling of nausea. Needed to take my mask off to get fresh air.  Nurse moved me to reclining chair and I proceeded to get very hot and feel like my heart was racing and skipping. The nurse noted some hitching and fast pulse, instructed me to take some breaths. And monitored my vitals. Noted my eyes feeling weird. They had epinephrine ready to draw up if my throat closed.. After 30 minutes I felt much better and they said my heart rate had slowed , I was able to leave.  About a half hour after leaving,  I got very tired, and my eyes still felt odd. Could feel my heart rate increasing again.  Began to get itchy/puffy eyes and nasal congestion with a tight chest.  I took a benadryl  and left work at the advisement of one our nurses to pull over and call emergency services if allergies turn anaphylatic.  Within 30 minutes of the benadryl allergies cleared up and I just needed to sleep.
chest pain; crushing feeling" in chest; crushing feeling" in heart; difficulty breathing; migraine-level" headache; arm soreness; This spontaneous case was reported by a consumer and describes the occurrence of CHEST PAIN (chest pain), CHEST DISCOMFORT (crushing feeling" in chest), CARDIAC DISORDER (crushing feeling" in heart), DYSPNOEA (difficulty breathing) and MIGRAINE (migraine-level" headache) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 046A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included COVID-19 ("severe" COVID-19 requiring hospital admittance in December 2020). Concurrent medical conditions included Anxiety. Concomitant products included LITHIUM from February 2021 to an unknown date, QUETIAPINE FUMARATE (SEROQUEL), NALTREXONE and LAMOTRIGINE (LAMICTAL) for an unknown indication.    On 04-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Apr-2021, the patient experienced MIGRAINE (migraine-level" headache) and PAIN IN EXTREMITY (arm soreness). On 07-Apr-2021, the patient experienced CHEST PAIN (chest pain), CHEST DISCOMFORT (crushing feeling" in chest), CARDIAC DISORDER (crushing feeling" in heart) and DYSPNOEA (difficulty breathing). The patient was treated with ACETYLSALICYLIC ACID (ASPIRIN (E.C.)) at an unspecified dose and frequency and GABAPENTIN at a dose of UNK, as necessary. On 06-Apr-2021, MIGRAINE (migraine-level" headache) and PAIN IN EXTREMITY (arm soreness) had resolved. At the time of the report, CHEST PAIN (chest pain), CHEST DISCOMFORT (crushing feeling" in chest), CARDIAC DISORDER (crushing feeling" in heart) and DYSPNOEA (difficulty breathing) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 07-Apr-2021, Heart rate: increased (High) Rapid heart rate.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Other Treatment drugs include Cyan pepper capsules to help her breath Patient has not contacted a physician nor the vaccinating pharmacy. Patient agreeable to seek care from a HCP if she experiences emergency symptoms (e.g., difficulty breathing, chest pain) in the future.
developed hives on face, arms and back within 72 hours after receiving the vaccine.  took benadryl which helped relieve symptoms.
A 61-year-old female patient received her 2nd dose of Pfizer COVID-19 vaccine. Within 15 minutes of administration, patient reported severe body weakness, dizziness and experienced uncontrollable tears.  Pharmacy called code white and patient refused 911 and asked pharmacy to monitor until her co-worker arrived. Patient requested pharmacy to call her work and inform them about the reaction. Her vitals were normal with BP of 135/80 HR of 85 at the time of the reaction. Normal breathing. No signs or symptoms of allergic reaction. Pharmacy provided food and water. Pharmacy continued to monitor the patient until her co-worker arrived.
Received only the adjuvant; Received only the adjuvant; This case was reported by a physician via call center representative and described the occurrence of inappropriate preparation of medication in a patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced inappropriate preparation of medication and inappropriate dose of vaccine administered. On an unknown date, the outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were unknown.  Additional details were provided as follows: The age at vaccination was not reported. The physician reported that a patient received Shingrix and was administered only the adjuvant (ASO1B) portion of the vaccine, which led to inappropriate preparation of medication and inappropriate dose of vaccine administered. The reporter did not have any other information about the patient. The physician could not confirm the date of incident nor details about the patient. The reporter consented to follow up.
Thrombocytopenia; This is a spontaneous report from a non-contactable consumer.   A female patient of an unspecified age received BNT162B2 (Pfizer-Biontech Covid-19 Vaccine) at single dose, on an unspecified date, for COVID-19 immunisation. Relevant medical history and concomitant medications were unknown. On an unspecified date, the patient experienced thrombocytopenia. Hospitalization required. Clinical outcome of the adverse event was unknown at time of this report.   No follow-up attempts are possible, information about lot number cannot be obtained.
She was reported to have had a heart attack the night after getting the vaccine and is in the hospital and remains there currently
I received the Moderna Booster  on 10-24-2021, everything was fine , just the arm pain as previously, the following week I started to have chest pain and headaches, they have not stopped and I am worried, I don?t have insurance, I flew to my previous state to have a mammogram, I flew back  and now they want me to go back for a second mammogram and a ultrasound, Now I am very concerned, the chest pain continues so is the headaches.
This spontaneous report was received from a pharmacist and refers to a patient of unknown age and gender. There was no information about the patient's concurrent conditions, concomitant therapies or medical history provided. On 10-NOV-2016, the patient was vaccinated with an expired dose of PNEUMOVAX 23 injection (lot # L008664 with an expiration date of 03-NOV-2016; exact dose was not reported), intramuscularly. No adverse effects were reported. There was no product quality complaint involved. Additional information has been requested.
Water blister on her left ankle and foot; A spontaneous report was received from a consumer concerning a 91-years-old female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced events water blister on her left ankle and foot/blister.  The patient's medical history was not provided. No relevant concomitant medications were reported.  On 6 Feb 2021, prior to the onset of the events the patient received first of two planned doses of mRNA-1273 (lot/batch: unknown) via unknown route for prophylaxis of COVID-19 infection.  On an unknown date, the patient experienced the event(s) water blister on her left ankle and foot.  No treatment information was provided.  Action taken with mRNA-1273 in response to the events was not reported.   The outcome of event(s), water blister on her left ankle and foot was unknown.
Reporting pain in both shoulders, hips, lower extremities. He has a difficult time lifting his arms overhead or donning his jacket. His legs feel heavy. He denies any specific areas of weakness or numbness. He has a history of joint pain and stiffness, not to this degree. ROS: Musculoskeletal: Nonantalgic gait. Wide based, slow to move. Muscle strength and tone appear normal. Negative Homans sign. Varicose veins bilateral lower extremities. Decreased range of motion of the shoulders, tenderness over the bursa on the shoulders and hips. Lumbar range of motion is affected with endpoint flexion and extension. He has some difficulty with balance with toe raises. There is no swelling of the joints. There is chronic deformity of the joints in the hands. AFTER treatment with prednisone: Significant improvement after starting the prednisone.
This spontaneous report as received from a licensed practical nurse and healthcare worker (reported also as: Health Department Employee) refers to an unspecified patients of unknown age and gender. Information regarding medical history and drug reactions or allergies was not reported. On an unknown date unspecified patients were vaccinated with ROTATEQ (dose, route of administration, anatomical location, lot#, expiration date not reported) that was improperly stored on 27-APR-2014. No product quality complaint (PQC) was reported. Concomitant medications were not reported. No adverse effect was reported. This is one of several reports received from the same source. Additional information has been requested.
welt that turned red, itched and is warm; Covid arm; right arm was little bit swollen; right arm was red; right arm was "warm to the touch"; right arm was itchy; it just looked puffy; it looked weird; there was a stripe from the shot site down my arm; headache,slight headache; chills; This spontaneous case was reported by a consumer and describes the occurrence of URTICARIA (welt that turned red, itched and is warm), VACCINATION SITE REACTION (Covid arm), PERIPHERAL SWELLING (right arm was little bit swollen), ERYTHEMA (right arm was red) and SKIN WARM (right arm was "warm to the touch") in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Blood pressure management, Atrial fibrillation, Allergy NOS and Blood cholesterol abnormal. Concomitant products included LEVOCETIRIZINE DIHYDROCHLORIDE (XYZAL) for Allergy, APIXABAN (ELIQUIS) for Atrial fibrillation, ATORVASTATIN for Blood cholesterol abnormal, DILTIAZEM and OLMESARTAN for Blood pressure management, VITAMIN D NOS, COENZYME Q10 [UBIDECARENONE], CENTRUM SILVER [ASCORBIC ACID;BETACAROTENE;BIOTIN;CALCIUM;CHROMIUM;COLECALCIFEROL;COPPER;FOLIC ACID;IODINE;IRON;LYCOPENE;MAGNESIUM;MANGANESE;NICOTINAMIDE;PANTOTHENIC ACID;PHOSPHORUS;PHYTOMENADIONE;POTASSIUM;PYRIDOXINE HYDROCHLORIDE;RETINOL;RIBOFLAVIN and CALCIUM, COLECALCIFEROL (CALCIUM PLUS VITAMIN D) for an unknown indication.   On 21-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1. On 22-Feb-2021, the patient experienced PERIPHERAL SWELLING (right arm was little bit swollen), ERYTHEMA (right arm was red), SKIN WARM (right arm was "warm to the touch"), PRURITUS (right arm was itchy), SKIN SWELLING (it just looked puffy), FEELING ABNORMAL (it looked weird), CUTANEOUS SYMPTOM (there was a stripe from the shot site down my arm), HEADACHE (headache,slight headache) and CHILLS (chills). On 23-Feb-2021, the patient experienced URTICARIA (welt that turned red, itched and is warm) and VACCINATION SITE REACTION (Covid arm). On 22-Feb-2021, HEADACHE (headache,slight headache) had resolved. On 25-Feb-2021, PERIPHERAL SWELLING (right arm was little bit swollen), ERYTHEMA (right arm was red), SKIN WARM (right arm was "warm to the touch"), PRURITUS (right arm was itchy), SKIN SWELLING (it just looked puffy), FEELING ABNORMAL (it looked weird), CUTANEOUS SYMPTOM (there was a stripe from the shot site down my arm) and CHILLS (chills) had resolved. At the time of the report, URTICARIA (welt that turned red, itched and is warm) and VACCINATION SITE REACTION (Covid arm) outcome was unknown.            No treatment information was provided.  Action taken with mRNA-1273 in response to the events was not Applicable.   Most recent FOLLOW-UP information incorporated above includes: On 26-May-2021: Newly added the relevant history, all concomitant medications and newly added the events.
Patient came in on 01/01/2022 and reported that he had Moderna vaccine on 12/30/2021 and feels like after 4 hours later he developed rashes to his both underarms , and lips first. than it went away after 36 hours. pts than developed rashes around waist area which was red rashes and itching no pain. pts had no rashes at injection sites all these time. pts been advised see doctor as soon as possible.
Swollen upper arm; red rash beneath injection site; Fever; Body ache; chills; This is a spontaneous report from a contactable consumer. A 72-years-old non pregnant female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for Injection, Lot number: EN6203) via an unspecified route of administration, administered in Arm Left on 20Feb2021 at 12:45 (at the age of 72-years-old) as dose 2, single for Covid-19 immunization. The patient's medical history was not reported. No known allergies. Concomitant medications included levothyroxine (MANUFACTURER UNKNOWN); diclofenac (MANUFACTURER UNKNOWN); omeprazole (MANUFACTURER UNKNOWN); oxybutynin hydrochloride (MANUFACTURER UNKNOWN), all for an unspecified indication, from an unspecified date and unknown if ongoing. No other vaccine received in four weeks. The patient previously received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EN5318) administered in arm right on 31Jan2021, 12:30 PM as dose 1 for Covid-19 immunization. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. No known allergies reported. On 21Feb2021 at 18:00, patient experienced fever, body aches and chills. It was reported that swollen upper arm and red rash beneath injection site first noticed on 22Feb2021 around 7 AM. Patient did not received treatment. The outcome of the events was not resolved.  Follow-up attempts completed. No further information expected.
Patient stated she started having pain in her left arm not too long after receiving her vaccine.  She states she is having trouble raising her arm above her head and reaching behind her back.  Patient states she has been using small weights to try to build up her endurance.  She did not state she has tried anything else.
little bit shoulder itchy; skin broke up a little bit/He thought has a reaction to the shot; rash on his skin, like redness/He thought has a reaction to the shot; Is not a painful issue but is kind of worried little bit; This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (little bit shoulder itchy), VACCINATION SITE RASH (skin broke up a little bit/He thought has a reaction to the shot), VACCINATION SITE ERYTHEMA (rash on his skin, like redness/He thought has a reaction to the shot) and ANXIETY (Is not a painful issue but is kind of worried little bit) in a 56-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 045A21A and 023M20A) for COVID-19 vaccination.     No Medical History information was reported.   On 02-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PRURITUS (little bit shoulder itchy), VACCINATION SITE RASH (skin broke up a little bit/He thought has a reaction to the shot), VACCINATION SITE ERYTHEMA (rash on his skin, like redness/He thought has a reaction to the shot) and ANXIETY (Is not a painful issue but is kind of worried little bit). At the time of the report, PRURITUS (little bit shoulder itchy), VACCINATION SITE RASH (skin broke up a little bit/He thought has a reaction to the shot), VACCINATION SITE ERYTHEMA (rash on his skin, like redness/He thought has a reaction to the shot) and ANXIETY (Is not a painful issue but is kind of worried little bit) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route), the reporter did not provide any causality assessments.   Age don't match with DOB Action taken with mRNA-1273 in response to the events was  not applicable No concomitant medications were given No treatment information was provided
This spontaneous report was received from a physician referring to a patient of unknown age and gender. Information regarding the patient's pertinent medical history, concurrent conditions, known allergies and concomitant medications was not reported. On an unknown date, the patient was vaccinated with an improperly stored dose of VARIVAX with lot # M007287 and expiration date on 12-FEB-2018 (anatomical route of vaccination was not provided) for prophylaxis. It was reported that, VARIVAX was exposed to a temperature of > 5 °F but < 14 °F for a 5 minutes time frame. The vaccine was not involved in a previous temperature excursion and data logger was not stated. Furthermore, it was reported that, no adverse events were suffered and that no product quality issue was involved. This is one of several reports received from the same reporter. Additional information has been requested.; Sender's Comments: US-009507513-1702USA004768:
feels like her hand fell asleep; bruise at the injection site; arm felt numb like it was falling asleep; This is a spontaneous report from a contactable Consumer. This 70-year-old female Consumer (patient) reported that she received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation, Solution for injection, Lot Number and Expiration date was not reported) via an unspecified route of administration, administered in left arm on an unspecified date as dose 1, single for COVID-19 immunization. The patient medical history and concomitant medications were not report-ed. The patient reported that she received her first Pfizer COVID vaccine in her left arm 1 week ago Monday (on an unspecified date). The patient looked up the side effects. About a half hour later (on an unspecified date) after receiving the vaccine her arm it "feels like her hand fell asleep". The patient was asking if this was a side effect. She also reported having a bruise at the injection site (the size of a nickel). The patient was concerned as no one she talked to had bruising at the injections site. She asked if this was a common occurrence and if so what was the percentage of people who experienced this. The patient reported that "no one cares". The patient was curious "what do I do about the second dose, do I get it. What happens if I don't get it are there any harmful side effects to not getting the second dose" and was asking "if the first and second doses are the same medicine and dose" The patient was asking if there were any harmful effects if someone received only 1 dose of the vaccine series and was asking for guidance on if she should get the second dose. Stated "there must be some people who can't take the second dose so what happened to them" The patient wondered "once you have the first dose do you have to have the second dose". The patient was curious, what percentage of people got the first shot and it felt like their hand on the side of the vaccine injection falls asleep, was that common. The outcome of the events was unknown.  No follow-up attempts are possible. Information about lot/ batch no cannot be requested.
Hives around injection site only, swelling of eyelids and around mouth, itching in throat Given benadrul 50mg PO x1, vitals checked eveyr 15 min for 1 hour Symptoms improved 20 min after benadryl, only residual throat itching at 1 hour mark Never had swelling lips/tongue, difficulty breathing, abdominal pain, or widespread rash
Initial report was received 12 October 2012 from a health care professional which identified a patient that was involved in a cluster of approximately 17 patients who tested PCR positive for influenza A/H3 since January. The other patients are captured in cases 2012-05658, 2012-05660, 2012-06067, 2012-06068, 2012-06069, 2012-06070, 2012-06071, 2012-06072, 2012-06073, 2012-09565 and 2012-05659. A female patient had received on 27 October 2011 FLUZONE, lot number UT4998AA (not a valid sanofi pasteur lot number (route and site not reported), and an unspecified amount of time later, the patient tested PCR positive for influenza A/H3. The approximate treatment date and collection date was reported as 26 March 2012. The patient's outcome was reported as recovered. No additional information was provided at the time of the report. Documents held by sender: None.
Information has been received from a registered nurse referring to a patient of unknown age and gender. Pertinent medical history and drug reactions/allergies were not reported. The primary reporter stated the patient was administered last in the series of GARDASIL (0.5 ml, intramuscularly) First and second dose of GARDASIL were given on 02-OCT-2015, and 04-OCT-2015 (unspecified lot/expiration date). Third dose in the series was GARDASIL 9 (0.5 ml, intramuscularly, unspecified lot/expiration date), which administered on 11-MAR-2016. No adverse effect was reported. Additional information is not expected as there was no consent for follow up.